#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10912	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2127	506.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	610	C	591	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10912	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2127	506.5	0	HET	.	.	.	C207T,A,G	.	207	207	C	433	433	C	616	C,T,A,G	341,236,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20134	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3704	539.6	0	.	n	.	0	T695C	SNP	695	695	T	1113	1113	C	669	C,T	649,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20134	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3704	539.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2389	2389	C	616	C,G	597,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20134	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3704	539.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2463	2463	A	590	A	580	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20134	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3704	539.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3015	3015	C	572	C,T	554,4	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	20134	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3704	539.6	0	HET	.	.	.	A1638G	.	1638	1638	A	2056	2056	A	619	A,G	324,275	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1442	folP	855	855	100.0	folP.l6.c4.ctg.1	1566	91.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1031	1033	AGC	128;128;129	A;G;C	124;125;126	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4260	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3304	127.3	1	SNP	p	S91F	1	.	.	271	273	TTC	592	594	TTC	154;154;152	T;T,C;C	151;146,6;149	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4260	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3304	127.3	1	SNP	p	G95N	0	.	.	283	285	GGC	604	606	GGC	144;144;147	G;G,A;C	141;138,4;143	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4260	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3304	127.3	1	SNP	p	D95G	1	.	.	283	285	GGC	604	606	GGC	144;144;147	G;G,A;C	141;138,4;143	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1224	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1328	91.3	1	SNP	p	G45D	0	.	.	133	135	GGC	453	455	GGC	135;134;133	G;G,A;C	134;132,1;131	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	606	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	884	67.6	0	.	n	.	0	A197.	DEL	197	197	A	538	538	A	133	A	130	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3858	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2842	134.3	1	SNP	p	D86N	0	.	.	256	258	GAC	549	551	GAC	140;140;139	G;A;C	135;133;138	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3858	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2842	134.3	1	SNP	p	S87R	1	.	.	259	261	CGT	552	554	CGT	139;137;138	C,A;G;T	134,2;134;133	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3858	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2842	134.3	1	SNP	p	R87I	0	.	.	259	261	CGT	552	554	CGT	139;137;138	C,A;G;T	134,2;134;133	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3858	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2842	134.3	1	SNP	p	R87W	0	.	.	259	261	CGT	552	554	CGT	139;137;138	C,A;G;T	134,2;134;133	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3858	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2842	134.3	1	SNP	p	S88P	0	.	.	262	264	TCC	555	557	TCC	137;137;136	T;C;C	135;133;133	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3188	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2646	119.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1590	1592	GGC	155;153;152	G;G;C	152;151;149	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	A311V	0	.	.	931	933	GCC	1223	1225	GCC	146;146;148	G;C;C,A	141;142;142,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	I312M	1	.	.	934	936	ATG	1226	1228	ATG	148;146;145	A;T,C;G,C	144;142,1;140,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	V316T	1	.	.	946	948	ACC	1238	1240	ACC	147;145;147	A,G;C,T;C,G	136,1;138,1;140,1	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	T316P	0	.	.	946	948	ACC	1238	1240	ACC	147;145;147	A,G;C,T;C,G	136,1;138,1;140,1	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1739	1741	ACC	131;133;132	A;C;C	123;130;129	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1793	1795	GCG	123;124;126	G;C;G	121;122;123	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1793	1795	GCG	123;124;126	G;C;G	121;122;123	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1916	1918	GGT	112;112;112	G,A;G;T,C	109,1;111;106,2	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1925	1927	AGC	109;109;109	A,G;G;C	101,2;109;105	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	2950	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2313	122.8	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1943	1945	CCG	87;88;86	C,G;C,G;G	76,1;75,1;69	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4192	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3053	136.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1595	1597	CCG	148;145;143	C,T;C,T;G,C	135,1;140,1;137,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1802	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1815	98.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	623	623	C	113	C,G	103,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	260	porB1a	984	297	91.03	porB1a.l15.c17.ctg.2	347	26.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	73	75	AAT	15;15;15	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	260	porB1a	984	297	91.03	porB1a.l15.c17.ctg.2	347	26.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	76	78	AAT	15;15;14	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	260	porB1a	984	297	91.03	porB1a.l15.c17.ctg.2	347	26.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	100	102	GCA	11;10;10	G;C;A	11;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	260	porB1a	984	297	91.03	porB1a.l15.c17.ctg.2	347	26.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	123	125	GTA	11;11;12	G;T;A	11;11;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	260	porB1a	984	297	91.03	porB1a.l15.c17.ctg.2	347	26.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	132	132	A	12	A	12	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2152	porB1b	1038	1038	100.0	porB1b.l6.c30.ctg.1	1619	130.8	1	SNP	p	G120K	1	.	.	358	360	AAG	618	620	AAG	171;171;169	A,G,C;A,G;G,T,A	160,4,2;163,4;153,4,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2152	porB1b	1038	1038	100.0	porB1b.l6.c30.ctg.1	1619	130.8	1	SNP	p	N121D	0	.	.	361	363	AAC	621	623	AAC	169;169;169	A,G;A,C;C,A	163,4;161,4;155,2	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2152	porB1b	1038	1038	100.0	porB1b.l6.c30.ctg.1	1619	130.8	1	SNP	p	A121N	1	.	.	361	363	AAC	621	623	AAC	169;169;169	A,G;A,C;C,A	163,4;161,4;155,2	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7222	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4873	147.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	834	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1068	77.1	1	SNP	p	V57M	1	.	.	169	171	ATG	505	507	ATG	160;163;162	A;T;G	159;160;160	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
